IMW 2019 | RVD/KRD: 3 drug combinations as the standard frontline induction

Paul Richardson

Dr Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, highlights the superiority of 3 drug platforms and touches on why he believes there is value in saving the most effective drugs to be used after relapse. This was discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video  
Similar topics